Carmen Munteanu
Research Subjects
Carmen Munteanu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Denis Keohane
Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA
7 shared publications - Thibaud Damy
Dept. of Cardiology, Hôpitaux Universitaires Henri Mondor, AP-HP, Université Paris Est Créteil (UPEC), CEPIA team INSERM U955 ; F-CRIN GRACE, 94000 Créteil
7 shared publications - Francesco Cappelli
Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy
6 shared publications - Eduardo Villacorta
Department of Cardiology, Complejo Asistencial Universitario de Salamanca, P°. de San Vicente 58, 37007 Salamanca, Spain
4 shared publications - Kristen Hsu
13Amyloidosis Research Consortium, Newton, MA
4 shared publications - Lucia Ponti
University of Urbino
4 shared publications
Latest Publications
- 9 May 2024
- Published by Morressier GmbH
Transthyretin amyloid cardiomyopathy among patients with hypertrophic cardiomyopathy: cardiac imaging and electrocardiographic findings from the TTRACK study PB93 (#19)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Transthyretin amyloid cardiomyopathy among patients with hypertrophic cardiomyopathy: cardiac imaging and electrocardiographic findings from the TTRACK study PB93 (#19)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study PB49 (#20)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study PB49 (#20)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with unexplained hypertrophic cardiomyopathy: results of the TTRACK study PB50 (#21)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with unexplained hypertrophic cardiomyopathy: results of the TTRACK study PB50 (#21)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER